Sitryx presents new preclinical data highlighting PKM2 as a promising metabolic target for the treatment of atopic dermatitis at the Inflammatory Disease Skin Summit 2025 November 13, 2025
Sitryx presents new preclinical data highlighting MTHFD2 as a novel metabolic target in autoimmune disease at ACR Convergence 2025 October 29, 2025
Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis October 2, 2025
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 March 21, 2025
Sitryx Therapeutics Makes Key Sppointments to Dtrengthen Business Operations and Progress Immunometabolism-Targeting Pipeline into Clinical Development March 5, 2024
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases January 4, 2024
